The Baltic – Ukrainian Atherosclerosis Conference will be held in hybrid format in Tallinn on 10.11.2023 at Hilton Tallinn Park Hotel (Fr. R. Kreutzwaldi 23), event will be preceded by Conference pre-session „Familial hypercholesterolemia round-table” on 09.11.23 (same venue). Click baner to see more!

We are so happy to announce that Professor Dimitri P. Mikhailidis from the UCL has received the first ILEP Honorary Membership Award. Thank you to all of you for the unanimous support of this award to Professor Mikhailidis.  And it is not only related to the fact that prof. Mikhailidis was a co-founder of the […]

In our next meta-analysis (the largest in the world) we showed a significant inverse association between daily step count and all-cause mortality and CV mortality with more the better over the cut-off point of 3867 steps/day for all-cause mortality and only 2337 steps for CV mortality. This confirms that we can start even with the […]

Within the group of the recognized Polish experts, based on the data from the PL-ACS Registry, for the first time in the world we confirmed that the upfront combination lipid-lowering therapy is superior to statin monotherapy for all-cause mortality in patients with ACS. These results suggest that in high-risk patients, such an approach, rather than […]

Within LBPMC Group we also evaluated the relationship between electronic nicotine delivery systems (ENDS) use and the risk of stroke when compared to non-smokers. The results were presented at the ESC Congress in Amsterdam and published simultaneously in the Archives of Medical Science.  https://www.archivesofmedicalscience.com/Association-between-electronic-nicotine-delivery-systems-use-and-risk-of-stroke-a,171473,0,2.html 

Please see the most recent ILEP expert opinion paper, just published in the European Heart Journal, on the role of low carbohydrate diet/ketogenic diet on the concentration and management of evaluated lipoprotein(a) level. – https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad635/7285571?login=false 

Statins are a widely available, cheap, safe, and extremely effective means to reduce the cardiovascular disease (CVD) risk, and it is therefore a tragedy that these life-saving medicines are under-used. Non-adherence to statin therapy reaches up to 60% after 2 years, and cessation is associated with a significant increase in the risk of CVD events. Much of this […]

Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many […]

Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially ameliorates the risk and is associated with long-term reduction in cardiovascular (CV) events. The robust evidence supporting these therapies supports their continued (and expanding) role in risk reduction. In addition […]

Abstract Aims Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different […]